Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 2Phase 1/2 1

Status

Completed 4Withdrawn 1

Sponsor Class

INDUSTRY 5

Study Type

Interventional 5

Sponsor

Cancer Type

Gastrointestinal 3Genitourinary 2Gynecologic 1

Conditions

Colorectal Neoplasms 2Prostatic Neoplasms 1Prostate Cancer Metastatic 1Colorectal and Ovarian Cancer Patients With Liver Metastases 1

Interventions

pembrolizumab 1033Carboplatin 971Paclitaxel 942Gemcitabine 799Cisplatin 757Docetaxel 698Bevacizumab 637Nivolumab 520Pemetrexed 507Capecitabine 475Cyclophosphamide 473Fluorouracil 425Dexamethasone 410Rituximab 391Oxaliplatin 352Injections 347Trastuzumab 314atezolizumab 312Cetuximab 291Leucovorin 290Irinotecan 271130-nm albumin-bound paclitaxel 257Prednisone 251Ipilimumab 244Doxorubicin 241Lenalidomide 231Fulvestrant 226fludarabine 219durvalumab 211Erlotinib Hydrochloride 196

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
INDUSTRY × Abituzumab × Clear all
NCT03688230 2020-03-18

AMELION

SFJ Pharmaceuticals, Inc.

Phase 2 Withdrawn
Gastrointestinal

Colorectal Neoplasms

NCT00958477 2017-08-02

A Study to Determine the Safety, Tolerability, Pharmacokinetics and Dynamic Effects of Different Doses of the Study Drug EMD 525797 in Prostate Cancer

Merck KGaA, Darmstadt, Germany

Phase 1 Completed
26 enrolled 44 charts
Genitourinary

Prostatic Neoplasms

NCT01008475 2016-03-30

POSEIDON

Merck KGaA, Darmstadt, Germany

Phase 1/2 Completed
232 enrolled 20 charts
Gastrointestinal

Colorectal Neoplasms

NCT00848510 2015-12-14

EMD 525797 in Colorectal and Ovarian Cancer Patients With Liver Metastases

Merck KGaA, Darmstadt, Germany

Phase 1 Completed
41 enrolled 18 charts
GastrointestinalGynecologic

Colorectal and Ovarian Cancer Patients With Liver Metastases

NCT01360840 2015-12-14

PERSEUS

EMD Serono

Phase 2 Completed
180 enrolled 23 charts
Genitourinary

Prostate Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡